FY2026 medical budget lines and team-level resource capacity. All figures USD; FY2026 exchange-rate snapshot of 2 Jan 2026.
Planned
Committed
Actual
Forecast at year end
Overrun-risk rule (MET-071): committed > planned, or actual ÷ planned > 0.75 × 1.05 = 78.75% with 71% of the fiscal year elapsed. Forecast is a straight-line assumption: actual ÷ 0.71. It ignores seasonality and known one-off commitments.
USD millions
| Product | Planned | Committed | Actual |
|---|---|---|---|
| Vantrexa | $8.4M | $7.34M | $5.13M |
| Nephrada | $4.2M | $2.09M | $1.33M |
| Lumeva | $3.6M | $3.51M | $2.84M |
| Aurelin | $1.08M | $0.75M | $0.52M |
USD millions, sorted by planned
Largest category: Personnel ($6.31M planned). 12 categories in the current filter.
MET-070 monthly history (Global, % of planned) against an even 1/12-per-month plan line. Filters do not apply to this series.
Latest: 71% consumed by Sep versus 75% on the straight line. Consumption above the line means spend is running ahead of an even phasing.
| Line | Product | Region | Function | Category | Initiative | Vendor | Planned | Committed | Actual | Variance | Consumed | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL-001 | Vantrexa | Global | Field Medical | Personnel | INI-0101 | — | $2.4M | $2.4M | $1.8M | $620k | 74% | On plan |
| BL-002 | Vantrexa | Global | Medical Communications | Publication | INI-0103 | Kessler Medical Writing | $420k | $380k | $262k | $158k | 62% | On plan |
| BL-003 | Vantrexa | Global | Medical Communications | Congress | INI-0106 | — | $1.1M | $1.1M | $698k | $432k | 62% | On plan |
| BL-004 | Vantrexa | Europe | Field Medical | Medical education | INI-0104 | — | $380k | $366k | $296k | $84k | 78% | On plan |
| BL-005 | Vantrexa | Global | Evidence Generation | Research | INI-0102 | Meridian Health Analytics | $1.4M | $620k | $310k | $1.1M | 21% | On plan |
| BL-006 | Vantrexa | Global | Medical Communications | Agency | INI-0105 | Clearview Health Communications | $640k | $610k | $512k | $128k | 80% | Overrun risk |
| BL-007 | Vantrexa | Global | Leadership | Advisory boards | — | — | $310k | $290k | $244k | $66k | 79% | On plan |
| BL-008 | Vantrexa | Global | Field Medical | Travel | — | — | $480k | $480k | $388k | $92k | 81% | Overrun risk |
| BL-009 | Vantrexa | Asia-Pacific · JP | Field Medical | Personnel | INI-0107 | — | $620k | $620k | $372k | $248k | 60% | On plan |
| BL-010 | Vantrexa | Asia-Pacific · JP | Medical Communications | Translation | — | — | $140k | $120k | $68k | $72k | 49% | On plan |
| BL-011 | Vantrexa | Global | Medical Operations | Technology | — | — | $220k | $220k | $165k | $55k | 75% | On plan |
| BL-012 | Vantrexa | Global | Evidence Generation | Data | — | — | $210k | $180k | $35k | $175k | 17% | On plan |
| BL-013 | Nephrada | Global | Field Medical | Personnel | — | — | $980k | $980k | $640k | $340k | 65% | On plan |
| BL-014 | Nephrada | Global | Medical Communications | Publication | — | Kessler Medical Writing | $220k | $200k | $118k | $102k | 54% | On plan |
| BL-015 | Nephrada | Global | Medical Communications | Congress | — | — | $380k | $340k | $192k | $188k | 51% | On plan |
| BL-016 | Nephrada | Global | Field Medical | Medical education | INI-0201 | — | $290k | $260k | $164k | $126k | 57% | On plan |
| BL-017 | Nephrada | Global | Evidence Generation | Research | INI-0202 | — | $2.1M | $85k | $85k | $2.0M | 4% | On plan |
| BL-018 | Nephrada | Europe | Leadership | Advisory boards | INI-0203 | — | $85k | $85k | $41k | $44k | 48% | On plan |
| BL-019 | Nephrada | Global | Medical Communications | Agency | — | — | $145k | $140k | $92k | $53k | 63% | On plan |
| BL-020 | Lumeva | Global | Field Medical | Personnel | — | — | $1.4M | $1.4M | $1.0M | $340k | 75% | On plan |
| BL-021 | Lumeva | Global | Medical Communications | Publication | INI-0301 | — | $180k | $170k | $128k | $52k | 71% | On plan |
| BL-022 | Lumeva | Global | Medical Communications | Congress | INI-0302 | — | $340k | $320k | $241k | $99k | 71% | On plan |
| BL-023 | Lumeva | Global | Evidence Generation | Research | — | — | $1.1M | $1.1M | $1.0M | $108k | 91% | Overrun risk |
| BL-024 | Lumeva | Global | Field Medical | Medical education | — | — | $240k | $210k | $160k | $80k | 67% | On plan |
| BL-025 | Lumeva | Global | Medical Information | Personnel | INI-0303 | — | $340k | $340k | $262k | $78k | 77% | On plan |
| BL-026 | Aurelin | Global | Leadership | Personnel | — | — | $620k | $620k | $470k | $150k | 76% | On plan |
| BL-027 | Aurelin | Global | Medical Communications | Publication | — | — | $110k | $90k | $42k | $68k | 38% | On plan |
| BL-028 | Aurelin | Global | Leadership | Consultancy | INI-0401 | — | $120k | $0 | $0 | $120k | 0% | On plan |
| BL-029 | Aurelin | Global | Medical Communications | Congress | — | — | $45k | $40k | $12k | $33k | 27% | On plan |
| BL-030 | Aurelin | Global | Evidence Generation | Research | — | — | $180k | $0 | $0 | $180k | 0% | On plan |
Team-level analytics only
8 of 10 teams have demand above capacity.
| Team | Region | Function | Capacity FTE | Demand FTE | Utilisation | Contractor FTE | Critical roles | Allocations by initiative |
|---|---|---|---|---|---|---|---|---|
| Field Medical — US Oncology | North America | Field Medical | 8 | 8.6 | 108% | 0 |
| |
| Field Medical — EU Oncology | Europe | Field Medical | 10 | 10.2 | 102% | 1 | — | |
| Field Medical — Japan | Asia-Pacific | Field Medical | 1 | 2 | 200% | 0 |
|
|
| Field Medical — Nephrology | Europe | Field Medical | 3 | 3.4 | 113% | 0 |
| |
| Field Medical — Neurology | Global | Field Medical | 6 | 5.1 | 85% | 0 | — | |
| Medical Communications | Global | Medical Communications | 5 | 6.1 | 122% | 2 |
| |
| Medical Information | Global | Medical Information | 9 | 9.8 | 109% | 1 | — | |
| Evidence Generation & HEOR | Global | Evidence Generation | 4 | 4.9 | 123% | 1 |
| |
| Medical Operations | Global | Medical Operations | 3 | 2.8 | 93% | 0 | — | Not allocated to initiatives |
| Compliance & Quality (MA-aligned) | Global | Compliance | 1 | 1.7 | 170% | 0 |
| Not allocated to initiatives |